EA259

BCRP Inhibition Assessment – BCRP-MDCK

This BCRP transporter assay is used to screen for inhibition of BCRP by a test compound, by measuring its effect on the bidirectional permeability of a BCRP substrate through BCRP-MDCK cell monolayers

Required from Customer

  • Either a minimum of 300 µL of test compound at 10 mM in DMSO, or 5 mg of powder
  • Exact molecular mass of test compound and its salt form
  • Solubility and chemical stability of the test compound in Hanks’ buffer
  • MSDS or handling and storage information,
    e.g., light sensitive, store at -20°C, etc.

Deliverables

  • Apparent permeability (Papp) of cladribine in both directions, in the presence and absence of test compound
  • Efflux ratio [(Papp B to A)/(Papp A to B)] of cladribine in the presence and absence of test compound
  • Classification of test compound as a likely inhibitor or non-inhibitor of BCRP at the concentration tested

Substrate

  • Test compound and cladribine each at 10 µM in modified Hanks’ buffer (HBSSg) with final DMSO concentration < 0.8%

Assay System

  • Confluent monolayers of BCRP-MDCK cells, 7-14 days old, in Transwell® dual-chamber plates, with apical and basolateral pH 7.4

Assay Conditions

  • Dose duplicate monolayers (N=2) on apical side for A to B cladribine permeability
  • Dose duplicate monolayers (N=2) on basolateral side for B to A cladribine permeability
  • Repeat above steps on monolayers pretreated and co-dosed with test compound on both apical and basolateral sides
  • Sample both apical and basolateral sides at 120 minutes
  • Determine the concentration of cladribine using a generic LC-MS/MS method with a minimum 4-point calibration curve

Assay QC

  • Verify the quality of the cell monolayer batch using control compounds before the monolayers are released for use
  • Verify the quality of each monolayer used in an assay by a pre-experiment TEER measurement and by calculating the Papp for the co-dosed control compound, Lucifer yellow

Notes

  1. The results from this assay are provided to the customer in the ExpressPlus report format, which may include graphical representations of data and comparison with historical data for reference compounds.
  2. The solubility of the test compound in Hanks’ buffer containing < 0.8% DMSO must be greater than the test concentration. If the solubility of the test compound is unavailable, Absorption Systems can conduct a solubility assessment at an additional charge.

Options

  1. The customer can request:
    • that a positive control be performed in parallel (additional fees apply)

ORDER ONLINE

REGISTER TO VIEW PRICES